---
figid: PMC3303935__nihms335230f1
figtitle: Toll-Like Receptors in Chronic Pain
organisms:
- Escherichia coli
- Staphylococcus aureus
- Porphyromonas gingivalis
- Mycobacterium avium
- Streptococcus sp. group B
- Escherichia coli 14A
- Microcystis aeruginosa
- Microcystis viridis CL4
- Mus musculus
- Rattus norvegicus
- Castor fiber
- Homo sapiens
- Drosophila melanogaster
- Gallus gallus
- Human immunodeficiency virus 1
- prion
pmcid: PMC3303935
filename: nihms335230f1.jpg
figlink: /pmc/articles/PMC3303935/figure/F1/
number: F1
caption: 'Numerous TLRs are expressed and activated in astrocytes including TLRs 2,
  3, 4, 5, 7, and 9. Several ligands have been found to activate certain TLRs in astrocytes
  including, but not limited to: lipoteichoic acid (LTA) (TLR2), soluble CD14 (TLR2),
  peptidoglycan (PGN) (TLR2, TLR4 TLR9), flagellin (TLR2, TLR4, TLR9), bacterial CpGs
  (TLR4, TLR5), high mobility group box-1 (HMGB1) (TLR2, TLR4), double-stranded RNA
  (dsRNA) (TLR3), lipopolysaccharide (LPS) (TLR4, TLR9) and Imiquimod (TLR7). Upon
  astrocytic TLR activation, numerous mediators are released, resulting in proinflammation.
  Such mediators include the proinflammatory cytokines: interleukin-6 (IL-6), interleukin-1alpha
  (IL-1α), tumor necrosis factor-alpha (TNF-α), IL-5, IL-13, IL-12p40, in addition
  to numerous proinflammatory mediators and chemokines: monocyte chemotactic protein-1
  (MCP-1), reactive oxygen species (ROS), RANTES, interferon-beta (IFN-β), CXCL10,
  CCL5, inducible nitric oxide synthase (iNOS) and nitric oxide (NO). All TLRs, are
  known to signal via the MyD88 pathway excluding TLR3 which utilises the Toll/IL1
  receptor (TIR) adaptor protein TRIF (Toll-receptor-associated activator of interferon),
  and TLR4 which can signal via both MyD88 and TRIF. Upon astrocytic TLR activation
  however, certain signalling components have been shown to be upregulated. TLR2 activation
  in astrocytes for example, has been demonstrated to utilise the co-receptor CD14.
  Furthermore, upon TLR4 activation, the TRIF-dependent pathway of TLR4 signalling
  has been shown to be inactive in astrocytes and utilizes the co-receptors MD-2 and
  CD14. (; ; ; ; ; ; ; ).'
papertitle: Toll-Like Receptors in Chronic Pain.
reftext: Lauren Nicotra, et al. Exp Neurol. ;234(2):316-329.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8731501
figid_alias: PMC3303935__F1
figtype: Figure
organisms_ner:
- Gallus gallus
- Rattus norvegicus
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
redirect_from: /figures/PMC3303935__F1
ndex: ea290cfa-df14-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3303935__nihms335230f1.html
  '@type': Dataset
  description: 'Numerous TLRs are expressed and activated in astrocytes including
    TLRs 2, 3, 4, 5, 7, and 9. Several ligands have been found to activate certain
    TLRs in astrocytes including, but not limited to: lipoteichoic acid (LTA) (TLR2),
    soluble CD14 (TLR2), peptidoglycan (PGN) (TLR2, TLR4 TLR9), flagellin (TLR2, TLR4,
    TLR9), bacterial CpGs (TLR4, TLR5), high mobility group box-1 (HMGB1) (TLR2, TLR4),
    double-stranded RNA (dsRNA) (TLR3), lipopolysaccharide (LPS) (TLR4, TLR9) and
    Imiquimod (TLR7). Upon astrocytic TLR activation, numerous mediators are released,
    resulting in proinflammation. Such mediators include the proinflammatory cytokines:
    interleukin-6 (IL-6), interleukin-1alpha (IL-1α), tumor necrosis factor-alpha
    (TNF-α), IL-5, IL-13, IL-12p40, in addition to numerous proinflammatory mediators
    and chemokines: monocyte chemotactic protein-1 (MCP-1), reactive oxygen species
    (ROS), RANTES, interferon-beta (IFN-β), CXCL10, CCL5, inducible nitric oxide synthase
    (iNOS) and nitric oxide (NO). All TLRs, are known to signal via the MyD88 pathway
    excluding TLR3 which utilises the Toll/IL1 receptor (TIR) adaptor protein TRIF
    (Toll-receptor-associated activator of interferon), and TLR4 which can signal
    via both MyD88 and TRIF. Upon astrocytic TLR activation however, certain signalling
    components have been shown to be upregulated. TLR2 activation in astrocytes for
    example, has been demonstrated to utilise the co-receptor CD14. Furthermore, upon
    TLR4 activation, the TRIF-dependent pathway of TLR4 signalling has been shown
    to be inactive in astrocytes and utilizes the co-receptors MD-2 and CD14. (; ;
    ; ; ; ; ; ).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LITAF
  - IL6
  - IL13
  - IL5
  - TLR7
  - IL8L2
  - IL12B
  - MYD88
  - CD14
  - HMGB1
  - HMGB3
  - TLR2
  - TLR2A
  - TICAM1
  - IRF7
  - TLR3
  - IL1B
  - IFNW1
  - CCL5
  - NOS2
  - MD
  - TLR5
  - TLR4
  - Tnf
  - Il6
  - Il1a
  - Il13
  - Il5
  - Ccl2
  - Tlr7
  - Myd88
  - Ephb1
  - Mapk8
  - Cd14
  - Lta
  - Hmgb1
  - Hbp1
  - Tlr2
  - Nfkb1
  - Rela
  - Rnf138
  - Irf3
  - Tlr3
  - Akt1
  - Ccl5
  - Il1b
  - Ifnb1
  - Ccl3
  - Nos2
  - Cxcl10
  - Tlr9
  - Tlr5
  - Tlr4
  - TNF
  - IL1A
  - CCL2
  - IRF6
  - SPG7
  - CXCL8
  - EPHB2
  - MAPK1
  - MAPK3
  - MAPK8
  - MAPK9
  - MAPK10
  - NDUFA2
  - LTA
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - TRIM69
  - IRF3
  - AKT1
  - AKT2
  - AKT3
  - IFNB1
  - CCL3
  - ISYNA1
  - CXCL10
  - TLR9
  - Mcpt1
  - Spg7
  - Il12b
  - Ephb2
  - Mapk1
  - Trim69
  - Ticam1
  - Ticam2
  - egr
  - Erk7
  - rl
  - bsk
  - Dsp1
  - tlr-2
  - Dif
  - dl
  - Rel
  - Akt
  - Inos
  - Nos
  - md
  - E(spl)mdelta-HLH
  - Toll-4
---
